Shaw AT, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study. J Clin Oncol 35, 2017 (suppl; abstr LBA9008).
ECCO 2017: Grote verschillen in Nederland bij opvolgen behandelrichtlijnen kanker
jan 2017 | Borstkanker, Longoncologie, Maag-darm-leveroncologie, Uro-oncologie